News

GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...
BioSpace17h
GSK Bets Up To $12B for Multi-Program Cancer Pact With Hengrui
The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...